Vietnam Medical and Pharmaceutical Investment JSC (HOSE:JVC)
Vietnam
· Delayed Price · Currency is VND 4,220.00
+10.00 (0.24%)
At close: Apr 28, 2026
HOSE:JVC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2017 | FY 2016 | 2015 - 2012 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | 2015 - 2012 |
| Revenue | 763,153 | 611,540 | 576,287 | 499,432 | 507,338 | Upgrade
|
| Revenue Growth (YoY) | 24.79% | 6.12% | 15.39% | -1.56% | -43.20% | Upgrade
|
| Cost of Revenue | 614,236 | 463,969 | 437,424 | 405,451 | 503,951 | Upgrade
|
| Gross Profit | 148,917 | 147,572 | 138,863 | 93,981 | 3,386 | Upgrade
|
| Selling, General & Admin | 96,122 | 111,062 | 111,556 | 120,726 | 1,195,390 | Upgrade
|
| Operating Expenses | 96,122 | 111,062 | 111,556 | 120,726 | 1,195,390 | Upgrade
|
| Operating Income | 52,796 | 36,510 | 27,308 | -26,745 | -1,192,003 | Upgrade
|
| Interest Expense | -14,682 | -5,437 | -5,292 | -4,599 | -16,473 | Upgrade
|
| Interest & Investment Income | 998.19 | 6,909 | 6,508 | 337.06 | 376.76 | Upgrade
|
| Currency Exchange Gain (Loss) | -1,299 | 1,895 | 1,879 | -1,628 | -5,874 | Upgrade
|
| Other Non Operating Income (Expenses) | 8,706 | 1,386 | 7,664 | 10,816 | 14,026 | Upgrade
|
| EBT Excluding Unusual Items | 46,518 | 41,262 | 38,067 | -21,819 | -1,199,948 | Upgrade
|
| Gain (Loss) on Sale of Investments | 13,067 | 18,049 | 14,754 | -750 | -110,750 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1,869 | -446.33 | 3,103 | -7,078 | 1,561 | Upgrade
|
| Asset Writedown | - | - | - | - | -26,884 | Upgrade
|
| Pretax Income | 61,454 | 58,865 | 55,924 | -29,647 | -1,336,021 | Upgrade
|
| Income Tax Expense | 11,504 | 18,529 | 3,284 | 2,047 | -239.13 | Upgrade
|
| Earnings From Continuing Operations | 49,950 | 40,336 | 52,640 | -31,694 | -1,335,782 | Upgrade
|
| Minority Interest in Earnings | -4.73 | -53.87 | -5.46 | - | - | Upgrade
|
| Net Income | 49,945 | 40,282 | 52,634 | -31,694 | -1,335,782 | Upgrade
|
| Net Income to Common | 49,945 | 40,282 | 52,634 | -31,694 | -1,335,782 | Upgrade
|
| Net Income Growth | 23.99% | -23.47% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 113 | 113 | 113 | 113 | 113 | Upgrade
|
| Shares Outstanding (Diluted) | 113 | 113 | 113 | 113 | 113 | Upgrade
|
| Shares Change (YoY) | - | - | - | - | 43.62% | Upgrade
|
| EPS (Basic) | 443.96 | 358.06 | 467.86 | -281.73 | -11873.60 | Upgrade
|
| EPS (Diluted) | 443.96 | 358.00 | 467.86 | -281.73 | -11873.60 | Upgrade
|
| EPS Growth | 24.01% | -23.48% | - | - | - | Upgrade
|
| Free Cash Flow | -130,408 | 69,159 | -49,837 | 33,540 | -327,834 | Upgrade
|
| Free Cash Flow Per Share | -1159.18 | 614.75 | -442.99 | 298.13 | -2914.07 | Upgrade
|
| Gross Margin | 19.51% | 24.13% | 24.10% | 18.82% | 0.67% | Upgrade
|
| Operating Margin | 6.92% | 5.97% | 4.74% | -5.36% | -234.95% | Upgrade
|
| Profit Margin | 6.54% | 6.59% | 9.13% | -6.35% | -263.29% | Upgrade
|
| Free Cash Flow Margin | -17.09% | 11.31% | -8.65% | 6.72% | -64.62% | Upgrade
|
| EBITDA | 77,236 | 71,812 | 74,762 | 42,899 | -1,116,762 | Upgrade
|
| EBITDA Margin | 10.12% | 11.74% | 12.97% | 8.59% | -220.12% | Upgrade
|
| D&A For EBITDA | 24,441 | 35,302 | 47,454 | 69,644 | 75,241 | Upgrade
|
| EBIT | 52,796 | 36,510 | 27,308 | -26,745 | -1,192,003 | Upgrade
|
| EBIT Margin | 6.92% | 5.97% | 4.74% | -5.36% | -234.95% | Upgrade
|
| Effective Tax Rate | 18.72% | 31.48% | 5.87% | - | - | Upgrade
|
| Revenue as Reported | 763,153 | 611,540 | 576,287 | 499,432 | 507,338 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.